Artivion, Inc. reports developments for a cardiac and vascular surgery medical device business focused on aortic disease. Recurring updates cover aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, along with preservation services for cardiac and vascular tissues and product sales across international markets.
Company news also includes quarterly and annual financial results, clinical presentations tied to NEXUS and AMDS aortic-disease programs, FDA and PMA-related regulatory developments, financing and capital-structure actions, investor conference participation, and governance matters. The company’s disclosures often connect revenue trends to stent grafts, On-X, BioGlue, preservation services, and other product categories used by cardiac and vascular surgeons.
Artivion (NYSE: AORT) reported third-quarter 2026 revenue of $123.8 million, up 9% from the same quarter of 2025. GAAP net loss was $7.9 million, or $0.16 per diluted share, versus net income of $6.5 million, or $0.13 per diluted share. Adjusted EBITDA fell 8% to $22.5 million.
The company narrowed its 2026 revenue outlook to $484–$492 million from $480–$496 million and adjusted EBITDA outlook to $93–$98 million from $92–$99 million. Guidance includes approximately $8 million of expense associated with the Endospan acquisition, completed in May. Following U.S. premarket approvals for AMDS and NEXUS, Artivion plans a January 2027 U.S. commercial launch for NEXUS; its ARCEVO LSA trial remains on schedule for enrollment. Cash was $48.399 million at September 30, versus $64.908 million at year-end 2025; net long-term debt rose to $363.787 million from $215.114 million.
Artivion (AORT) will participate in investor conferences on November 10 and November 11, 2026, with management presenting at both events.
The Stifel 2026 Healthcare Conference presentation begins at 11:20 a.m. ET; the 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum presentation begins at 8:00 a.m. ET. Both will be webcast on Artivion's Investors page, with replays available for 90 days.
Artivion (NYSE: AORT) will release its third-quarter 2026 financial results after the market closes on November 5, 2026. A teleconference and live webcast will follow at 4:30 p.m. ET, with a question-and-answer session hosted by Chairman, President and Chief Executive Officer Pat Mackin.
Artivion (NYSE:AORT) reported second quarter 2026 revenue of $125.8 million, up 11% on a GAAP basis and 9% on a non-GAAP constant currency basis versus 2025. Growth was led by On-X mechanical valves and stent grafts, which grew 18% and 12% in constant currency, respectively.
The company posted a GAAP net loss of $13.5 million (−$0.28 per diluted share) versus prior-year net income of $1.3 million, while non-GAAP net income was $6.3 million ($0.13 per share) versus $10.7 million in 2025. Adjusted EBITDA rose 7% to $26.4 million. Artivion completed the acquisition of Endospan, adding the NEXUS Aortic Arch Stent Graft System, and received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis. For full-year 2026, the company reiterated revenue guidance of $480–$496 million (7–11% adjusted constant currency growth) and adjusted EBITDA guidance of $92–$99 million, including about $8 million of Endospan-related expenses.
Artivion (NYSE:AORT) will participate in two investor conferences in August 2026. Management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:30 a.m. ET at the InterContinental Boston Hotel, with a live webcast and 90-day archive on Artivion's investor webpage. The company will also hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026, though no webcast will be available.
Artivion (NYSE:AORT) will release its second quarter 2026 financial results on Thursday, August 6, 2026, after the market close. The company will host a teleconference and live webcast at 4:30 p.m. ET the same day, led by Chairman, President and CEO Pat Mackin, including a Q&A session.
Investors can join the live call by dialing 201-689-8261. A replay will be available about one hour after the event via 877-660-6853 or 201-612-7415, using conference number 13760537. Live and archived webcasts, along with the earnings release containing financial and statistical information, will be accessible in the Investors section of www.artivion.com.
Artivion (NYSE:AORT) received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with malperfusion, about 60% of such cases.
Approval removes HDE-related IRB requirements, is backed by PERSEVERE trial data, and targets a $150 million estimated annual U.S. market.
Artivion (NYSE:AORT) will participate in the 2026 Truist Securities MedTech Conference on June 16, 2026, at the Boston Harbor Hotel.
The company will host a fireside chat at 1:00 p.m. ET, with a live and archived webcast available on its investor relations website.
Artivion (NYSE:AORT) closed the acquisition of Endospan, following April 2026 FDA PMA approval of the NEXUS Aortic Arch System, described as the first off-the-shelf endovascular solution for high-risk aortic arch disease. The deal includes a $175M purchase price (less prior loan offsets) plus up to $200M contingent on U.S. NEXUS commercial performance over two years.
The transaction adds NEXUS and its custom configurations (NEXUS DUO, NEXUS TRE) to Artivion’s existing AMDS and ARCEVO LSA offerings, expanding its global aortic arch portfolio across EMEA, Europe, Asia-Pacific and Latin America.
Artivion (NYSE:AORT) completed the acquisition of endovascular aortic arch specialist Endospan, developer of the NEXUS Aortic Arch System. The $135 million upfront net purchase price was funded using a previously drawn $150 million delayed draw term loan, with additional performance-based consideration possible.
The NEXUS branched endovascular stent graft system received FDA PMA approval in April 2026. Artivion has distributed NEXUS in EMEA since 2019 and, according to the company, this deal completes its three-part aortic arch portfolio alongside AMDS and ARCEVO LSA, adding a pipeline of next-generation arch technologies.